Judge orders hearing on CVS/Aetna merger

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CVS's RSI Indicator exited the oversold zone, 16 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 52%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 54 cases where CVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.

Following a +6.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 222 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

The Aroon Indicator entered an Uptrend today. In 173 of 253 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 49 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.

The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 29 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.

CVS moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CVS crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.346) is slightly lower than the industry average of (3.520). P/E Ratio (21.950) is within average values for comparable stocks, (126.353). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.032) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.